サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1679375

肺腺がん治療市場規模、シェア、動向分析レポート：療法別、最終用途別、地域別、セグメント別予測、2025年～2030年

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
肺腺がん治療市場規模、シェア、動向分析レポート：療法別、最終用途別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年02月28日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肺腺がん治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の肺腺がん治療市場規模は2025～2030年にかけて10.7％のCAGRを記録し、2030年には111億8,000万米ドルに達すると予測されています。

この市場は、非小細胞肺がん（NSCLC）のサブタイプである肺腺がんの管理と治療を目的とした幅広い治療オプション、技術、サービスを提供しています。

特定の地域における喫煙率の上昇、大気汚染や職業上の危険などの環境要因が市場成長の主要促進要因です。肺腺がんと診断される人が増えるにつれて、効果的な治療オプションに対する需要も高まっています。

肺がんの症状や危険因子に関する意識の高まりは、市場に大きな影響を与えています。禁煙と早期発見についての啓蒙を目的とした公衆衛生キャンペーンにより、症状を経験した後すぐに医療機関を受診する人が増加しました。

2023年10月、Bristol Myers Squibbは、進行非小細胞肺がんに対するKRASG12C阻害剤であるKRAZATI（アダグラシブ）を含む偶発的価値のある権利により、総額48億米ドルの株式価値、58億米ドルの可能性を有するMiratiを1株当たり58米ドルで買収しました。

肺腺がん治療市場レポートハイライト

  • 化学療法セグメントは2024年に36%の最大売上シェアを占めました。これは主に、肺がん治療におけるその確立された役割と、治療レジメンの継続的な進歩によるものです。
  • 免疫療法セグメントは最も急速な成長が見込まれ、予測期間中のCAGRは13.5%と予測されます。肺腺がんの有病率の上昇により、化学療法や放射線療法などの従来の治療法と比較して、より優れた有効性と安全性を提供する先進的な治療オプションに対する需要が高まっている
  • 病院は、その包括的なインフラと幅広い先進的ながん治療を提供する能力によって、2024年には63.9％の最大の収益シェアを占めました。
  • 専門クリニックセグメントは、予測期間中に最も速いCAGRで成長すると予想されます。この成長の原動力は、個別化治療や標的治療に対する需要の高まりと、肺がん治療の選択肢に対する患者の意識の高まりです。
  • 北米の肺腺がん治療市場は、肺腺がんの罹患率の上昇と治療アプローチの革新への強い注目によって、2024年には39.5％の最大の売上シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肺腺がん治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 分析-ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析

第4章 肺腺がん治療市場：療法ビジネス分析

  • 療法市場シェア、2024年と2030年
  • 療法セグメントダッシュボード
  • 市場規模と予測と動向分析、療法別、2018～2030年
  • 化学療法
  • 標的療法
  • 免疫療法
  • 放射線療法
  • その他

第5章 肺腺がん治療市場：最終用途ビジネス分析

  • 最終用途市場シェア、2024年と2030年
  • 最終用途セグメントダッシュボード
  • 市場規模と予測と動向分析、最終用途別、2018～2030年
  • 病院
  • 専門クリニック
  • その他

第6章 肺腺がん治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018～2030年
  • 北米
    • 国別、2018～2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 国別、2018～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 国別、2018～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別、2018～2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 国別、2018～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Pfizer Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • F. Hoffmann-La Roche Ltd
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 Global lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 North America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 U.S. lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Mexico lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 UK lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 UK lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Germany lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Italy lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Denmark lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Denmark lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Japan lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 China lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 China lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 India lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 India lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Australia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Australia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 South Korea lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 South Korea lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Thailand lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Latin America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Brazil lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Argentina lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 63 UAE lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lung Adenocarcinoma Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end use outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lung adenocarcinoma treatment market dynamics
  • Fig. 12 Lung adenocarcinoma treatment market: Porter's five forces analysis
  • Fig. 13 Lung adenocarcinoma treatment market: PESTLE analysis
  • Fig. 14 Lung adenocarcinoma treatment market: Treatment segment dashboard
  • Fig. 15 Lung adenocarcinoma treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Other market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung adenocarcinoma treatment market: End use segment dashboard
  • Fig. 22 Lung adenocarcinoma treatment market: End use market share analysis, 2024 & 2030
  • Fig. 23 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 25 Other market, 2018 - 2030 (USD Million)
  • Fig. 26 Lung Adenocarcinoma Treatment Market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework
目次
Product Code: GVR-4-68040-428-6

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.
  • The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.
  • Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.
  • The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.
  • North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Lung adenocarcinoma treatment market: Type Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other Market, 2018 - 2030 (USD Million)

Chapter 5. Lung adenocarcinoma treatment market: End use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Lung adenocarcinoma treatment market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AstraZeneca
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Eli Lilly and Company
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AbbVie Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Astellas Pharma Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. F. Hoffmann-La Roche Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives